Advertisement

Emerging Therapies for Amyloidosis

  • Merrill D. BensonEmail author
Chapter
Part of the Current Clinical Pathology book series (CCPATH)

Abstract

Tremendous progress has been made in the last 20 years for the treatment of the systemic amyloidoses and new treatments continue to be tested. The treatment of AL (immunoglobulin light chain) amyloidosis with high-dose intravenous melphalan with autologous stem-cell rescue and a number of newer drugs that control plasma cell dyscrasia have extended life for many patients. Liver transplantation which may extend life for ATTR (transthyretin) patients may eventually be replaced by newer drugs that inhibit hepatic production of TTR or alter the pathway to fibril formation.

Keywords

Amyloidosis Specific therapies Liver transplantation Antisense oligonucleotide siRNA 

References

  1. 1.
    Sipe JD, Benson MD, Buxbaum JN, Ikeda S, Merlini G, Saraiva MJ, Westermark P. Amyloid fibril protein nomenclature: 2010 recommendations from the nomenclature committee of the International Society of Amyloidosis. Amyloid. 2010;17:101–4.CrossRefPubMedGoogle Scholar
  2. 2.
    Kastner DL, Aksentijevich I. Intermittent and periodic arthritis syndromes. In: Koopman WJ, Moreland LW, editors. Arthritis and allied conditions: a textbook of rheumatology, vol. 2. 15th ed. Philadelphia: Lippincott Williams and Wilkins; 2004. p. 1411–61. Chapter 68.Google Scholar
  3. 3.
    Kisilevsky R, Lemieux LJ, Fraser PE, Kong X, Hultin PG, Szarek WA. Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: implications for Alzheimer’s disease. Nat Med. 1995;1:143–8.CrossRefPubMedGoogle Scholar
  4. 4.
    Dember LM, Hawkins PN, Hazenberg BP, Gorevic PD, Merlini G, Butrimiene I, Livneh A, Lesnyak O, Puéchal X, Lachmann HJ, Obici L, Balshaw R, Garceau D, Hauck W, Skinner M. Eprodisate for the treatment of renal disease in AA amyloidosis. N Eng J Med. 2007;356:2349–60.CrossRefGoogle Scholar
  5. 5.
    Holmgren G, Ericzon BG, Groth CG, Steen L, Suhr O, Andersen O, Wallin BG, Seymour A, Richardson S, Hawkins PN, Pepys MB. Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. Lancet. 1993;341:1113–6.CrossRefPubMedGoogle Scholar
  6. 6.
    Holmgren G, Steen L, Ekstedt J, Groth CG, Ericzon BG, Eriksson S, Andersen O, Karlberg I, Nordén G, Nakazato M, Hawkins P, Richardson S, Pepys M. Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-met30). Clin Genet. 1991;40:242–6.CrossRefPubMedGoogle Scholar
  7. 7.
    Familial World Transplant Registry. http://www.fapwtr.org/ram_fap.htm. Accessed 2 Sept 2011.
  8. 8.
    Suhr O, Danielsson A, Holmgren G, Steen L. Malnutrition and gastrointestinal dysfunction as prognostic factors for survival in familial amyloidotic polyneuropathy. J Intern Med. 1994;235:479–85.CrossRefPubMedGoogle Scholar
  9. 9.
    Coelho T, Maia L, Martins da Silva A, Waddingtion-Cruz M, Planté-Bordeneuve V, Lozeron P, Suhr OB, Campistol J, Conceiçao IM, Conceiçao H, Schmidt H, Trigo P, Packman J, Grogan DR. Tafamidis (Fx-1006A): a first-in-class disease-modifying therapy for transthyretin familial amyloid. Amyloid. 2010;17:75–6.CrossRefGoogle Scholar
  10. 10.
    Berk JL, Suhr OB, Obici L, Sekijima Y, Zeldenrust SR, Yamashita T, Heneghan MA, Gorevic PD, Litchy WJ, Wiesman JF, Nordh E, Corato M, Lozza A, Cortese A, Robinson-Papp J, Colton T, Rybin DV, Bisbee AB, Ando Y, Ikeda S, Seldin DC, Merline G, Skinner M, Kelly JW, Dyck PJ, Diflunisal Trial Consortium. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA. 2013;310:2658–67.PubMedCentralCrossRefPubMedGoogle Scholar
  11. 11.
    Nakamura M, Ando Y, Nagahara S, Sano A, Ochiya T, Maeda S, Kawaji T, Ogawa M, Hirata A, Terazaki H, Haraoka K, Tanihara H, Ueda M, Uchino M, Yamamura K. Targeted conversion of the transthyretin gene in vitro and in vivo. Gene Ther. 2004;11:838–46.CrossRefPubMedGoogle Scholar
  12. 12.
    Benson MD, Kluve-Beckerman B, Zeldenrust SR, Siesky AM, Bodenmiller DM, Showalter AD, Sloop KW. Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides. Muscle Nerve. 2006;33:609–18.CrossRefPubMedGoogle Scholar
  13. 13.
    Gillmore JD, Stangou AJ, Lachmann HJ, Goodman HJ, Wechalekar AD, Acheson J, Tennent GA, Bybee A, Gilbertson J, Rowczenio D, O’Grady J, Heaton ND, Pepys MB, Hawkins PN. Organ transplantation in hereditary apolipoprotein AI amyloidosis. Am J Transplant. 2006;6:2342–7.CrossRefPubMedGoogle Scholar
  14. 14.
    Gillmore JD, Stangou AJ, Tennent GA, Booth DR, O’Grady J, Rela M, Heaton ND, Wall CA, Keogh JA, Hawkins PN. Clinical and biochemical outcome of hepatorenal transplantation for hereditary systemic amyloidosis associated with apolipoprotein AI Gly26Arg. Transplantation. 2001;71:986–92.CrossRefPubMedGoogle Scholar
  15. 15.
    Benson MD, Liepnieks J, Uemichi T, Wheeler G, Correa R. Hereditary renal amyloidosis associated with a mutant fibrinogen α-chain. Nat Genet. 1993;3:252–5.CrossRefPubMedGoogle Scholar
  16. 16.
    Stangou AJ, Banner NR, Hendry BM, Rela M, Portmann B, Wendon J, Monaghan M, MacCarthy P, Buxton-Thomas M, Mathias CJ, Liepnieks JJ, O’Grady J, Heaton ND, Benson MD. Hereditary fibrinogen A α-chain amyloidosis: phenotypic characterization of a systemic disease and the role of liver transplantation. Blood. 2010;115:2998–3007.CrossRefPubMedGoogle Scholar
  17. 17.
    Pepys MB, Hawkins PN, Booth DR, Vigushin DM, Tennent GA, Soutar AK, Totty N, Nguyen O, Blake CCF, Terry CJ, Feest TG, Zalin AM, Hsuan JJ. Human lysozyme gene mutations cause hereditary systemic amyloidosis. Nature. 1993;362:553–7.CrossRefPubMedGoogle Scholar
  18. 18.
    Yazaki M, Farrell SA, Benson MD. A novel lysozyme mutation Phe57Ile associated with hereditary renal amyloidosis. Kidney Int. 2003;63:1652–7.CrossRefPubMedGoogle Scholar
  19. 19.
    Magy N, Liepnieks JJ, Yazaki M, Kluve-Beckerman B, Benson MD. Renal transplantation for apolipoprotein AII amyloidosis. Amyloid. 2003;10:224–8.CrossRefPubMedGoogle Scholar
  20. 20.
    Abrahamson M, Grubb A. Increased body temperature accelerates aggregation of the Leu-68 Gln mutant cystatin C, the amyloid-forming protein in hereditary cystatin C amyloid angiopathy. Proc Natl Acad Sci U S A. 1994;91:1416–20.PubMedCentralCrossRefPubMedGoogle Scholar
  21. 21.
    Benson MD, James S, Scott K, Liepnieks JJ, Kluve-Beckerman B. Leukocyte chemotactic factor 2: a novel renal amyloid protein. Kidney Int. 2008;74:218–22.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  1. 1.Department of Pathology and Laboratory MedicineIndiana University School of Medicine, Van Nuys Medical Science BuildingIndianapolisUSA

Personalised recommendations